Editorial

  1. Pfizer Executives Elaborate On Payer Biosimilar Contracting Goals, Challenges
    4/20/2018

    At a recent press conference, Pfizer executives shared a few key updates related to Inflectra’s uptake and the ongoing efforts to work with commercial payers. These updates not only shed more light on Inflectra’s market journey, but also reassured me that progress is being made — even though it’s not regularly broadcast in headlines.

  2. Stakeholders To Gather In London To Plan Biosimilar Market’s Future
    4/17/2018

    This year, The Biosimilar Medicines Group, a Medicines for Europe sector group, will host its 16th annual conference. While I will be unable to attend the event once again this year, I was thrilled to have the opportunity to chat with Carol Lynch, chair of the Biosimilar Medicines Group for Medicines for Europe, about the upcoming conference.

  3. The European Biosimilars Landscape: What To Expect In The Year Ahead
    4/10/2018

    The European biosimilars market is the most mature in the world and continues to gather momentum. Since January 2017, the European Commission (EC) has granted marketing authorization for 19 biosimilar therapeutic medicines that reference seven distinct originator biologics, making it a record period in this region for biosimilar approvals. Overall, there are now over 40 EC-approved biosimilar products, across 15 different biologic classes (as of March 31, 2018).

  4. Indication- And Reference-Based Pricing: A Positive For Biosimilar Manufacturers?
    4/3/2018

    Biosimilar manufacturers may gain under a reference-based pricing scenario, as they have some, or all, of their originator’s indications and are already priced lower than their biologic counterparts.

  5. 3 Biosimilar Barriers In Community Clinics
    4/3/2018

    In the first of this two-part article, McKesson experts share insights on two biosimilar barriers they’ve noticed in community clinics and highlight their takeaways from infliximab’s and filgrastim’s experiences tackling these barriers.

  6. Partnering With Insurers To Improve Biosimilar Access In The U.S.
    3/28/2018

    Drug developers have found a powerful ally in their campaign to advance biosimilar adoption in the U.S. — the nation’s health insurance providers. Insurers are keen to drive down the price of reference biologics, and they view biosimilars as an important way to accomplish that goal.

  7. 90 Studies Prove Biosimilars’ Safety And Efficacy: What Now?
    3/27/2018

    This review sought to answer two questions which have been plaguing the biosimilar industry since day one: will biosimilar switching have any impact on safety, and will biosimilars be the harbingers of increased immunogenicity? And it has provided us with far more than just answers to these questions.

  8. Unlocking The Potential Of Real-World Data: Tapping Into Today’s Data To Improve Healthcare Tomorrow
    3/27/2018

    Healthcare is undergoing a shift in how key stakeholders approach and evaluate patient data -- driven by growing access to and general use of real-world data, such as de-identified patient data collected and analyzed from registries, electronic health records, wearable devices, and administrative and healthcare claims databases. This type of data is increasingly being utilized by industry representatives to help inform device development, health system operations, formularies and resulting coverage, and patient care decisions.

  9. Electrospinning & The Future Of Continuous Pharmaceutical Manufacturing
    3/26/2018

    Blair Brettmann, Ph.D., assistant professor in Georgia Tech’s School of Materials Science and Engineering, discusses the current state of continuous manufacturing in the pharmaceutical industry, her group’s research into electrospinning and other novel approaches, and how to overcome the challenges to further adoption of continuous processes.

  10. Does The U.S. Biosimilar Space Have A Case Of “Progressophobia?”
    3/22/2018

    A prediction that a failure of the U.S. biosimilars market could lead to the end of the global biosimilars market begs the question of how we evaluate progress, as well as how such a prediction could be avoided.